Ambrx of San Diego Acquired by Fosun Pharma, WuXi PharmaTech and Others

Ambrx Inc., a clinical-stage San Diego antibody-conjugate biotech company, will be acquired by a consortium of China companies, including Fosun Pharma and WuXi PharmaTech, plus China equity investors HOPU and Everbright. The price was not disclosed. Last year, Ambrx filed for an IPO that valued the company at $223 million, but withdrew the offering. Ambrx, which has raised around $100 million of venture capital, has attracted many big names for partners, bringing in $200 million in deal payments. Its partnerships contain milestones that could total as much as $1.5 billion. More details.... Stock Symbols: (SHA: 600196; HK: 02196) (NYSE: WX) Share this with colleagues: // //